MOTS-c (Mitochondrial Peptide)

What Is MOTS-c? The Mitochondria-Encoded Peptide

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame nested within the 12S ribosomal RNA gene of the mitochondrial genome. Identified in 2015, it activates AMP-activated protein kinase through inhibition of the folate cycle, and translocates to the nucleus under metabolic stress to regulate nuclear gene expression.

Key facts

Full name
Mitochondrial ORF of the 12S rRNA type-c
Length
16 amino acids
Sequence
H-MRWQEMGYIFYPRKLR-OH
Molecular weight
2,174.6 Da
Molecular formula
C101H152N28O22S2
CAS number
1627580-64-6
PubChem CID
146675088
Identified
2015: Lee et al., Cell Metabolism

What makes MOTS-c unusual

Almost every peptide studied in this field is encoded in nuclear DNA and translated in the cytosol. MOTS-c is not. Its coding sequence sits inside the mitochondrial genome, specifically within the 12S ribosomal RNA gene, in a short open reading frame that overlaps a gene already doing another job. That places it in a small class of mitochondrial-derived peptides, and it means the mitochondrion is acting as a signalling organelle rather than only a site of energy metabolism.

Where it came from

MOTS-c was identified by Changhan Lee, Jiali Zeng, Brian Drew and colleagues at the University of Southern California, published in Cell Metabolism on 3 March 2015 under the title 'The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance' (PMID 25738459). The paper described both the peptide and its metabolic effects in mouse models.

Research material referenced

MOTS-C 10mg, third-party HPLC tested

Buy MOTS-C · £24.99

How it signals

MOTS-c activates AMP-activated protein kinase, but not through the canonical route of a rising AMP-to-ATP ratio. It inhibits the folate cycle and de novo purine biosynthesis, which causes AICAR (5-aminoimidazole-4-carboxamide ribonucleotide, an endogenous AMPK activator) to accumulate. AMPK activation follows from that accumulation. Downstream effects reported in the literature include GLUT4 translocation.

The nuclear finding

In 2018 the same group reported something less expected: under metabolic stress, MOTS-c moves from the mitochondrion into the nucleus and regulates nuclear gene expression, including antioxidant response element-containing genes (Kim, Son and Benayoun, Cell Metabolism, 4 September 2018, PMID 29983246). A peptide encoded in mitochondrial DNA that acts on nuclear transcription is a real two-way channel between the two genomes.

The exercise connection

Reynolds and colleagues reported in Nature Communications on 20 January 2021 (PMID 33473109) that MOTS-c is exercise-induced, with skeletal-muscle levels rising roughly 12-fold and circulating levels about 1.6-fold in humans following exercise. The paper characterised it as a regulator of age-dependent physical decline and muscle homeostasis, with the interventional work conducted in mice.

Where the literature stands

MOTS-c appears in roughly 250 indexed PubMed records. The great majority are preclinical (cell models and rodent studies), alongside human observational work on circulating concentrations. It is not an approved medicine in any jurisdiction and is supplied for laboratory research only.

Frequently asked questions

What does MOTS-c stand for?

Mitochondrial Open Reading Frame of the 12S rRNA type-c, which describes exactly where in the mitochondrial genome its coding sequence sits.

Is MOTS-c a hormone?

It is often described as one because it is released and acts at a distance, but it is more accurately a mitochondrial-derived signalling peptide. The distinction matters mainly because its origin is mitochondrial DNA rather than the nuclear genome.

Is MOTS-c approved for any use?

No. It holds no marketing authorisation anywhere and is supplied for laboratory research only.

Is MOTS-c on the WADA prohibited list?

Yes. It is prohibited in sport, which is worth knowing for anyone whose research context involves competitive athletes.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More MOTS-c (Mitochondrial Peptide) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.